Spectral AI reports FY2024 R&D revenue $29.6M; net loss $(15.3)M; plans FDA submission by Q2 2025

Spectral AI, Inc.

2025-Q1 EPS reported $0.11 revenue$6,707,000

FY2024 R&D revenue $29.6M (+63.5% YoY); net loss $(15.3)M ($(0.85)/share) vs $(20.9)M in FY2023.
Burn Validation Study: DeepView sensitivity 86.6% (image-wise) vs 40.8% for burn physicians; FDA De Novo submission planned by Q2 2025.
Cash $5.2M at Dec 31, 2024; raised $11.2M in Q1 2025 via $8.5M debt & $2.7M equity; FY2025 revenue guidance ~$21.5M.
CFO Vincent Capone amended employment: base salary $440k, bonus up to $250k; 100k RSUs vested, 75k stock options granted.
Spin-off of Spectral IP into public company expected by end of Q2 2025; warrants repriced from $11.50 to $2.75.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.